Every new formulation and generic drug needs to demonstrate bioequivalence to secure market approval. But each of these required tests can be complicated by innovations in drug delivery or dosing features, yielding unpredictable challenges if companies modify delivery techniques to try to improve bioavailability.
The 3rd Bioequivalence Summit is your must-attend event for achieving true interchangeability of both small molecule generics and biosimilars across multiple delivery platforms. No other conference goes into as much depth of scientific detail in order to help broaden the robustness and market uptake of your generic and biosimilar portfolio.
Conference - Early Bird Price before August 12th, 2016: USD 1895.00
Conference Standard Pricing after August 12th, 2016: USD 2095.00
Speakers: Joe Fuhr, Widener University, Sudhakar Koundinya, Dr. Reddy's Laboratories, Meena Venugopal, Alvogen Pharma, John Caminis, Baxalta, DongZhou Liu, PhD, GlaxoSmithKline, Isadore Kanfer, Leslie Dan Faculty of Pharmacy, Amitava Mitra, Merck & Co. Inc., Shrinivas Savale, Torrent Pharmaceuticals ltd., Audra Stinchcomb, University of Maryland School of Pharmacy, Magdalena Leszczyniecka, STC Biologics, Jerome Schentag, The University of Buffalo, Zahra Shahrokh, STC Biologics
Sign in to add slides, notes or videos to this session